Investigators indicated that comprehensive geriatric assessment could be used to determine whether older, frail patients with hematologic cancers can undergo intensive treatment with chemotherapy and whether curative treatment is viable.
Geriatric consultations vs standard of care for patients with hematologic malignancies who were pre-frail or frail did not significantly improve survival at 1 year but did increase discussions on end-of-life goals of care.
Elderly patients with multiple myeloma who were treated with first-line bortezomib had a higher risk of falls vs age-matched controls.
A phase 2 trial shows promise of the daratumumab/ixazomib combination in frail and elderly patients with multiple myeloma who are treated in the relapsed setting when given without dexamethasone.
Older patients undergoing treatment for B-cell malignancies who contracted the COVID-19 virus were at an increased risk of death vs patients with other cancers under the age of 60 years.
The phase 2 HORIZON study indicated that melflufen plus dexamethasone (Ozurdex) demonstrated clinically meaningful efficacy as well as a manageable safety profile in patients with heavily pretreated relapsed/refractory multiple myeloma.